CD38 targeted treatment for multiple myeloma

Area of Science:

• Oncology, Immunology

Background:

• CD38 antigen is uniformly expressed on plasma cells, making it an ideal target for multiple myeloma (MM) therapy.
• Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, are advanced treatments for MM.
• These mAbs possess pleiotropic mechanisms of action, including crucial immunomodulatory effects via depletion of immunosuppressive cells.

Purpose of the Study:

• To review the role and potential of anti-CD38 mAbs in treating multiple myeloma and other plasma cell dyscrasias.
• To highlight the efficacy, safety, and combination strategies involving anti-CD38 mAbs.
• To discuss the expanding applications of CD38-targeted therapy in hematological malignancies and beyond.

Main Methods:

• Review of clinical data and mechanisms of action for anti-CD38 mAbs (daratumumab, isatuximab).
• Analysis of combination regimens and their impact on patient outcomes.
• Exploration of applications in other hematological and oncological conditions.

Main Results:

• Anti-CD38 mAbs achieve partial response or better in approximately 30% of heavily pre-treated MM patients as monotherapy.
• Daratumumab is approved in combination regimens, notably with lenalidomide and dexamethasone, significantly prolonging progression-free survival.
• CD38-targeted therapies are effective in AL amyloidosis and are being investigated in other cancers and autoimmune disorders.

Conclusions:

• Anti-CD38 mAbs represent a significant advancement in MM treatment, with potential for cure in a subset of patients.
• Their favorable toxicity profile and distinct mechanisms make them attractive partners for standard anti-myeloma drugs.
• CD38-targeted therapy is moving towards first-line treatment and holds promise for broader applications in hematologic and other malignancies.